AGL 40.00 No Change ▼ 0.00 (0%)
AIRLINK 129.00 Decreased By ▼ -0.53 (-0.41%)
BOP 6.76 Increased By ▲ 0.08 (1.2%)
CNERGY 4.50 Decreased By ▼ -0.13 (-2.81%)
DCL 8.70 Decreased By ▼ -0.24 (-2.68%)
DFML 41.00 Decreased By ▼ -0.69 (-1.66%)
DGKC 81.30 Decreased By ▼ -2.47 (-2.95%)
FCCL 32.68 Decreased By ▼ -0.09 (-0.27%)
FFBL 74.25 Decreased By ▼ -1.22 (-1.62%)
FFL 11.75 Increased By ▲ 0.28 (2.44%)
HUBC 110.03 Decreased By ▼ -0.52 (-0.47%)
HUMNL 13.80 Decreased By ▼ -0.76 (-5.22%)
KEL 5.29 Decreased By ▼ -0.10 (-1.86%)
KOSM 7.63 Decreased By ▼ -0.77 (-9.17%)
MLCF 38.35 Decreased By ▼ -1.44 (-3.62%)
NBP 63.70 Increased By ▲ 3.41 (5.66%)
OGDC 194.88 Decreased By ▼ -4.78 (-2.39%)
PAEL 25.75 Decreased By ▼ -0.90 (-3.38%)
PIBTL 7.37 Decreased By ▼ -0.29 (-3.79%)
PPL 155.74 Decreased By ▼ -2.18 (-1.38%)
PRL 25.70 Decreased By ▼ -1.03 (-3.85%)
PTC 17.56 Decreased By ▼ -0.90 (-4.88%)
SEARL 78.71 Decreased By ▼ -3.73 (-4.52%)
TELE 7.88 Decreased By ▼ -0.43 (-5.17%)
TOMCL 33.61 Decreased By ▼ -0.90 (-2.61%)
TPLP 8.41 Decreased By ▼ -0.65 (-7.17%)
TREET 16.26 Decreased By ▼ -1.21 (-6.93%)
TRG 58.60 Decreased By ▼ -2.72 (-4.44%)
UNITY 27.51 Increased By ▲ 0.08 (0.29%)
WTL 1.41 Increased By ▲ 0.03 (2.17%)
BR100 10,450 Increased By 43.4 (0.42%)
BR30 31,209 Decreased By -504.2 (-1.59%)
KSE100 97,798 Increased By 469.8 (0.48%)
KSE30 30,481 Increased By 288.3 (0.95%)

AstraZeneca on Friday beat first-quarter sales and profit expectations and stood by its forecasts for 2022 as newer therapies for kidney disease and rare conditions offset an expected decline in COVID-19 vaccine sales.

It expects sales of its antibody-based COVID-19 treatment, Evusheld, to grow this year, but that will be more than outweighed by a decline in sales of its vaccine developed with Oxford University amid growing competition, concerns about its shelf life and vaccine hesitancy.

The vaccine recorded $1.15 billion in sales in the quarter, the majority of which came from initial contracts, while the antibody treatment brought in $469 million.

The two-dose shot was AstraZeneca’s second best-selling product in 2021 with sales of $3.9 billion.

AstraZeneca’s total revenue jumped 60% to $11.39 billion for the three months ended March 31 on a constant-currency basis.

Core earnings of $1.89 per share were helped by strong sales of products such as Farxiga for diabetes and kidney and the vaccine.

Analysts on average were expecting profit of $1.70 per share on revenue of $10.85 billion, Refinitiv IBES data showed.

However, sales of its top three oncology drugs - Tagrisso, Imfinzi and Lynparza - missed consensus expectations.

Even though COVID-19 levels are beginning to wane, access to cancer diagnoses and treatment has still not rebounded to pre-pandemic levels.

Comments

Comments are closed.